Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith A Perez

Showing results (101-110 of 324) with videos related to

Pageof 33
Sort By:
The Oncologist|June 9, 2017
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final ResultsMichael Andersson, José M López-Vega, Thierry Petit, et al.
Breast Cancer Research : BCR|December 14, 2016
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final resultsEdith A Perez, José Manuel López-Vega, Thierry Petit, et al.
JAMA Oncology|October 16, 2015
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast CancerEdith A Perez, Karla V Ballman, Kathy S Tenner, et al.
Clinical and Translational Medicine|January 20, 2017
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytesBrian M Necela, Bianca C Axenfeld, Daniel J Serie, et al.
American Journal of Clinical Oncology|August 8, 2012
A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338Vivek Roy, Barbara A Pockaj, Jacob B Allred, et al.
Human Pathology|September 19, 2009
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerSejal S Shah, Rhett P Ketterling, Matthew P Goetz, et al.
The New England Journal of Medicine|December 28, 2007
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerKathy Miller, Molin Wang, Julie Gralow, et al.
Cancer Immunology Research|July 4, 2014
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Nadine Norton, Rebecca M Olson, Mark Pegram, et al.
Mayo Clinic Proceedings|February 13, 2002
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridizationEdith A Perez, Patrick C Roche, Robert B Jenkins, et al.
Clinical Breast Cancer|June 28, 2006
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitorsBetty A Mincey, Mei Sheng Duh, Simu K Thomas, et al.
Pageof 33

Showing results (101-110 of 324) with videos related to

Sort By:
Pageof 33
The Oncologist|June 9, 2017
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final ResultsMichael Andersson, José M López-Vega, Thierry Petit, et al.
Breast Cancer Research : BCR|December 14, 2016
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final resultsEdith A Perez, José Manuel López-Vega, Thierry Petit, et al.
JAMA Oncology|October 16, 2015
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast CancerEdith A Perez, Karla V Ballman, Kathy S Tenner, et al.
Clinical and Translational Medicine|January 20, 2017
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytesBrian M Necela, Bianca C Axenfeld, Daniel J Serie, et al.
American Journal of Clinical Oncology|August 8, 2012
A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338Vivek Roy, Barbara A Pockaj, Jacob B Allred, et al.
Human Pathology|September 19, 2009
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancerSejal S Shah, Rhett P Ketterling, Matthew P Goetz, et al.
The New England Journal of Medicine|December 28, 2007
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerKathy Miller, Molin Wang, Julie Gralow, et al.
Cancer Immunology Research|July 4, 2014
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Nadine Norton, Rebecca M Olson, Mark Pegram, et al.
Mayo Clinic Proceedings|February 13, 2002
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridizationEdith A Perez, Patrick C Roche, Robert B Jenkins, et al.
Clinical Breast Cancer|June 28, 2006
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitorsBetty A Mincey, Mei Sheng Duh, Simu K Thomas, et al.
Pageof 33